Liposomes modified with a 16-histidine cell-penetrating peptide naturally targeted lysosomes inside cells and successfully delivered a replacement enzyme, offering a potential new treatment approach for lysosomal storage diseases.
Lysosome-specific targetingH16-modified liposomes naturally localized to lysosomes after cell entry, enabling targeted enzyme delivery to GLA-deficient cells
What the researchers found
A cell-penetrating peptide made of 16 histidine residues (H16) was successfully used to modify liposomes, creating a delivery system that enters cells and naturally targets lysosomes. The H16-modified liposomes (H16-Lipo) were internalized by human fibrosarcoma cells via multiple endocytosis pathways and localized specifically to intracellular lysosomes.
As proof of concept, the H16-Lipo delivered alpha-galactosidase A (GLA) — a lysosomal enzyme — to the lysosomes of GLA-knockdown cells and improved their proliferation. This demonstrates the system's potential for treating lysosomal storage diseases, where patients lack specific lysosomal enzymes.
Why it matters
Lysosomal storage diseases (LSDs) are a group of ~50 rare genetic disorders caused by missing lysosomal enzymes, affecting roughly 1 in 5,000 births. Current enzyme replacement therapies often struggle to get enzymes inside cells and specifically into lysosomes. A peptide-modified liposome that naturally targets lysosomes could dramatically improve drug delivery for these devastating conditions.
The numbers in context
H16 peptide: 16 histidine residues · Stearyl-H16 inserted into liposome membrane · Delivered alpha-galactosidase A (GLA) · Improved proliferation of GLA-knockdown cells · Human fibrosarcoma cell line
How the study worked
Researchers prepared liposomes modified with a stearyl-H16 peptide (the fatty acid anchor inserts into the liposome membrane). They tested cellular uptake in human fibrosarcoma cells, identified the endocytosis pathways involved, tracked intracellular localization, and then loaded the liposomes with GLA enzyme to test functional delivery to lysosomes in GLA-deficient cells.
Who was studied
Human fibrosarcoma cell line (in vitro)
What this study cannot tell us
This is an in vitro study using a single cancer cell line (fibrosarcoma), which may not reflect uptake in normal human cells or in vivo conditions. No animal studies were conducted. The abstract doesn't report quantitative uptake efficiency, GLA activity restoration levels, or comparison with existing enzyme replacement delivery methods. Long-term stability and immunogenicity of H16-Lipo were not assessed.
How to read the evidence
This is a preliminary in vitro study demonstrating proof of concept in a single cell line. While the lysosome-targeting result is novel and the functional enzyme delivery is promising, no animal or human data exists yet.
When this study was published
Published in 2018, this study established the H16 peptide-liposome concept. Research on polyhistidine-based delivery systems has continued to develop since then.
The bigger picture
Cell-penetrating peptides are one of the hottest areas in drug delivery research because they solve the fundamental problem of getting large molecules through cell membranes. This study adds a new dimension by showing that a specific CPP doesn't just get cargo inside cells — it delivers it to a specific organelle (lysosomes). This kind of subcellular targeting could transform treatment for the ~50 known lysosomal storage diseases and potentially other conditions requiring intracellular drug delivery.
Questions still open
- Does the H16-Lipo system maintain its lysosome-targeting ability in vivo, where the biological environment is far more complex than cell culture?
- Could this delivery platform be adapted for other lysosomal enzymes beyond GLA, potentially treating multiple lysosomal storage diseases?
- What is the mechanism that causes H16-Lipo to specifically localize to lysosomes rather than other intracellular compartments?
Common questions
What are lysosomal storage diseases and why are they hard to treat?
What makes the H16 peptide special as a drug delivery tool?
Read the original research
Drug delivery using polyhistidine peptide-modified liposomes that target endogenous lysosome.
Biochemical and biophysical research communications, 501(3), 648-653
Citation
Hayashi, Taiki; Shinagawa, Matsumi; Kawano, Tsuyoshi; Iwasaki, Takashi. (2018). Drug delivery using polyhistidine peptide-modified liposomes that target endogenous lysosome.. Biochemical and biophysical research communications, 501(3), 648-653. https://doi.org/10.1016/j.bbrc.2018.05.037